TP53 and neoplasm: Taken together, these data demonstrate that primary p53/MCA tumor development induces immune tolerance to tumor cells that coevolve with their immune system, which cannot be overcome by the immunostimulatory effects of increased neoantigen expression from in vitro growth, tumor cell injection, or treatment with RT and immunotherapy.